SNGX Stock Summary and Trading Ideas (Soligenix | NASDAQ:SNGX)

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely: The Public Health Solutions business segment includes development programs for RiVax, a ricin toxin vaccine candidate, GX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease and various vaccine programs, including a program targeting filoviruses and CiVax; and The Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte, utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL).

Soligenix trades on the NASDAQ stock market under the symbol SNGX.

As of June 12, 2026, SNGX stock price was flat at $0.43 with 684,442 million shares trading.

SNGX has a beta of 0.13, meaning it tends to be less sensitive to market movements. SNGX has a correlation of 0.00 to the broad based SPY ETF.

SNGX has a market cap of $6.37 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, SNGX traded as high as $32.00 and as low as $.28.

The top ETF exchange traded funds that SNGX belongs to (by Net Assets): VXF.

SNGX has underperformed the market in the last year with a price return of -76.6% while the SPY ETF gained +24.1%. SNGX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -64.8% and -52.7%, respectively, while the SPY returned +11.6% and -1.9%, respectively.

SNGX support price is $.38 and resistance is $.48 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SNGX shares will trade within this expected range on the day.